Stockreport

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field [Seeking Alpha]

Astria Therapeutics, Inc.  (ATXS) 
PDF ATXS stock has a compound called STAR-0310 in development for an immune disorder, with plans for a Phase 1a study in 2025. Despite positive early data for STAR-0215, [Read more]